CT-95 Trial for Advanced Cancers
Phase 1
70
about 3.8 years
18+
7 sites in CO, IL, MI +4
About this study
This trial is testing CT-95, a new drug, in people with advanced cancers that have Mesothelin. The goal is to see if CT-95 is safe and effective.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take CT-95
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Determine the MTD or RD of CT-95 [Safety and Tolerability], Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Secondary: Evaluate Overall Survival [Survival], Evaluate Progression-free Survival [Anti-tumor Activity], Evaluate the Area Under the Curve (AUC) [Pharmacokinetics], Evaluate the Maximum Serum Concentration (Cmax) [Pharmacokinetics]
Oncology, Respiratory